Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Stayble Therapeutics: BioStock: Stayble reports last patient last visit in the phase IIb study

Stayble Therapeutics

Stayble Therapeutics recently reached an important milestone in the development of a new treatment for patients suffering from chronic back pain. The last patient has completed all visits in the company's phase IIb study in degenerative disc disease. Now the most exciting part awaits - to see if the results can confirm the treatment's intended pain relief effect. BioStock contacted CEO Andreas Gerward to find out more about the milestone of having completed all patient follow-ups.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/09/stayble-reports-last-patient-last-visit-in-the-phase-iib-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.